The CNIO has devised a procedure to structure and expedite the preliminary phases of the Discovery and Development process for new drugs. The Experimental Therapies Programme (ETP) ) is meant to bridge the gap between basic research underway into the biology of cancer and the pharmaceutical sector.
Thanks to their broad experience in the pharmaceutical industry, ETP research teams bring the discovery process closer to completion beginning with the identification of a lead molecule – a “hit” obtained through sophisticated screening processes, or by applying the principles of rational design. In either case, the results will be candidate compounds –- leads -– that will subsequently be earmarked for clinical trials.
The programmeme has two components: Medical Chemistry, where compounds with a potential tumour suppressing effect are synthesized and optimized, and Biology, where those substances are tested in vitro and in vivo – on different types of mice.
The CNIO is a member of international alliances for the development of new drugs and therapies, such as the Academic Drug Discovery Consortium .We are likewise affiliated with the Milner Therapeutics Institute at Britain’s Cambridge University. The chart below details our pharmaceutical discovery projects underway at the present time.